newsfilter
← Latest News
GlobeNewswire·

NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update

-- Approval decisions from EMA, UK and Switzerland regulators for obicetrapib and obicetrapib/ezetimibe fixed dose combination expected in 2H26 -- -- Phase 3 PREVAIL CVOT blinded event rate tracking in line with